T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

Francesco Schettini; Benedetta Conte; Giuseppe Buono; Pietro De Placido; Sara Parola; Gaia Griguolo; Alessandra Fabi; Claudia Bighin; Ferdinando Riccardi; Daniela Cianniello; Michelino De Laurentiis; Fabio Puglisi; Giacomo Pelizzari; Marta Bonotto; Stefania Russo; Antonio Frassoldati; Antonio Pazzola; Filippo Montemurro; Matteo Lambertini; Valentina Guarneri; F. Cognetti; Mariavittoria Locci; Daniele Generali; Pierfranco Conté; Sabino De Placido; Mario Giuliano; Grazia Arpino; Lucia Del Mastro

doi:10.1016/j.esmoop.2021.100099

Abstract

Our study suggests superiority for P + T + taxane over T-DM1 as up-front treatment of early-relapsing HER2+ metastatic breast cancer, which merits further assessment in larger and prospective trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schettini et al. (2021) studied this question.

synapsesocial.com/papers/69dbd56c3d9adb00e7685314 https://doi.org/10.1016/j.esmoop.2021.100099

View Full Paper

Ask AI

Bookmark

Abstract

Our study suggests superiority for P + T + taxane over T-DM1 as up-front treatment of early-relapsing HER2+ metastatic breast cancer, which merits further assessment in larger and prospective trials.

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

Abstract

Discussion

Cite This Study

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading